Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

NCT03984357 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: PD-1 blocking antibody
DRUG: Gemcitabine
DRUG: Cisplatin
RADIATION: Intensity-modulated radiotherapy

Sponsor

Sun Yat-sen University

Collaborators

[object Object]